Pleasanton, United States
Inscripta, Inc., known as "The Digital Genome Engineering Company," stands as a beacon in the field of genome engineering. Founded in 2015, the company is headquartered in the United States and aims to revolutionize biomanufacturing with innovative technologies that support a cleaner, healthier, and sustainable world.
As a leader in the life sciences technology sector, Inscripta has made significant strides in the bioeconomy, offering critical technologies that facilitate new biotech innovations globally. Their facilities in Pleasanton and Burlingame, California, underscore their commitment to expanding and bolstering domestic biomanufacturing capabilities.
The company's last significant investment was a $150.00M Series E round in April 2021, featuring a high-caliber roster of investors including D1 Capital Partners, T. Rowe Price, Durable Capital Partners, Foresite Capital, Morgan Stanley, Fidelity Investments, and JS Capital Management. This strong backing underscores investor confidence in Inscripta's potential to drive substantial advancements in genome engineering.
